Abdominal adiposity largely explains associations between insulin resistance, hyperglycemia and subclinical atherosclerosis: The NEO study  by Gast, Karin B. et al.
at SciVerse ScienceDirect
Atherosclerosis 229 (2013) 423e429Contents lists availableAtherosclerosis
journal homepage: www.elsevier .com/locate/atherosclerosisAbdominal adiposity largely explains associations between insulin
resistance, hyperglycemia and subclinical atherosclerosis: The NEO
study
Karin B. Gast a,b,*, Johannes W.A. Smit c,1, Martin den Heijer a,d, Saskia Middeldorp e,
Ralph C.A. Rippe a, Saskia le Cessie a,f, Eelco J.P. de Koning g, J.W. Jukema h, Ton J. Rabelink g,
Albert de Roos i, Frits R. Rosendaal a,j, Renée de Mutsert a
for the NEO study group2
aDepartment of Clinical Epidemiology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
bDepartment of Internal Medicine, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
cDepartment of Endocrinology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
dDepartment of Internal Medicine, VU Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands
eDepartment of Vascular Medicine, Academic Medical Center, PO Box 22660, 1100 DD Amsterdam, The Netherlands
fDepartment of Medical Statistics and Bioinformatics, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
gDepartment of Nephrology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
hDepartment of Cardiology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
iDepartment of Radiology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
jDepartment of Thrombosis and Hemostasis, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlandsa r t i c l e i n f o
Article history:
Received 13 December 2012
Received in revised form
9 May 2013
Accepted 21 May 2013
Available online 1 June 2013
Keywords:
Atherosclerosis
Intima-media thickness
Cardiovascular disease
Insulin resistance
Hyperglycemia
Adiposity
Waist circumference* Corresponding author. Department of Clinical Epi
E-mail addresses: k.b.gast@lumc.nl (K.B. Gast), J
r.c.a.rippe@lumc.nl (R.C.A. Rippe), s.le_cessie@lumc.n
(T.J. Rabelink), a.de_roos@lumc.nl (A. de Roos), f.r.rose
1 Present address: The Radboud University Nijmege
2 See Appendix B.
0021-9150/$ e see front matter  2013 Elsevier Irela
http://dx.doi.org/10.1016/j.atherosclerosis.2013.05.021a b s t r a c t
Objective: The relative importance of insulin resistance and hyperglycemia to the development of
atherosclerosis remains unclear. Furthermore, adiposity may be responsible for observed associations.
Our aim was to study the relative contributions of adiposity, insulin resistance and hyperglycemia to
subclinical atherosclerosis.
Methods: In this cross-sectional analysis of the Netherlands Epidemiology of Obesity (NEO) study, a
cohort of persons of 45e65 years, BMI, waist circumference (WC), fasting glucose (FPG), HbA1c and in-
sulin concentrations were measured and the revised HOMA-IR was calculated. The carotid Intima-Media
Thickness (cIMT) was measured by ultrasound. We performed linear regression analyses between
standardized values of FPG, HbA1c, HOMA-IR, BMI, WC with cIMT, and subsequently included age, sex,
ethnicity, education and smoking, HOMA-IR, HbA1c and FPG, BMI and WC in the models.
Results: After exclusion of participants with glucose lowering therapy (n ¼ 356) or missing data
(n ¼ 252), this analysis included 6065 participants, 43% men, and mean (SD) cIMT of 616 (92) mm. Dif-
ferences in cIMT (95% CI) per SD were: FPG: 16 (10,21); HbA1c: 12 (7,16); HOMA-IR: 11 (6,16) mm. These
associations attenuated after adjustments, and attenuated most strongly after adjustment for WC. Dif-
ferences in cIMT (95% CI) per SD in the full model were: FPG: 4 (0,7); HbA1c: 2 (1,5); HOMA-IR: 0 (3,3);
BMI 16 (13,19); WC: 18 (14,21) mm.
Conclusion: In middle-aged individuals, we observed similar contributions of insulin resistance and hy-
perglycemia to subclinical atherosclerosis. These contributions were largely explained by abdominal
adiposity, emphasizing the importance of weight management.
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Type 2 diabetes increases the risk of cardiovascular disease 2e3-
fold [1,2]. Both insulin resistance and hyperglycemia may promote
atherosclerosis [3,4]. However, the relative importance of hyper-
glycemia and insulin resistance to the development of atheroscle-
rosis remains unclear.
Experimental studies have identiﬁed differential contributions
of hyperglycemia and insulin resistance to the development of
atherosclerosis. Insulin resistance may lead to atherosclerosis
through various mechanisms, including dyslipidemia and
inﬂammation [4]. Hyperglycemia may contribute to endothelial
dysfunction by several mechanisms, including oxidative stress,
increased production of advanced glycation endproducts and al-
terations in glycocalyx composition [3,5]. However, randomized
controlled trials in individuals with pre-diabetes and type 2 dia-
betes have not shown an effect of intensive glycemic control (i.e.
lowering HbA1c concentration) on the incidence of cardiovascular
events [6,7]. These results suggest that the contribution of hy-
perglycemia to the development of atherosclerosis may be
limited.
Observational studies in persons without glucose lowering
therapy have shown that measures of insulin resistance and
glucose concentrations were associated with carotid intima-media
thickness (cIMT) [8e10], a marker of subclinical atherosclerosis,
and cardiovascular disease [2,11,12]. These studies, however, have
not distinguished the contributions of hyperglycemia and insulin
resistance. Moreover, adiposity may result in insulin resistance,
consequential hyperglycemia and atherosclerosis and may there-
fore be responsible for observed associations. We hypothesize that
observed associations between insulin resistance, hyperglycemia
and atherosclerosis can be explained by adiposity (These hypo-
thetical pathways are depicted in Fig. 1).
Therefore, the aim of this study is to investigate the relative
contributions of adiposity, insulin resistance and hyperglycemia to
subclinical atherosclerosis, in a cohort of men and women without
glucose lowering therapy.2. Materials and methods
2.1. Study design and study population
The Netherlands Epidemiology of Obesity (NEO) study is a
population-based prospective cohort study in individuals aged 45e
65 years, with an oversampling of persons with a BMI of 27 kg/m2
or higher. This cohort was designed to prospectively study path-
ways that lead to disease in personswith overweight or obesity. The
present study is a cross-sectional analysis of the baseline mea-
surements of the participants included in the NEO study from the
start at September 3, 2008 until the end at September 28, 2012.Adiposity Insulin resistance Hyperglycemia Subclinical atherosclerosis
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Fig. 1. Hypothesis Path diagram. L: known and unknown confounding factors. Un-
derlying mechanisms of the paths A to E are indicated in the discussion.Detailed information about the study design and data collection has
been described elsewhere [13]. Men and women aged between 45
and 65 years with a self-reported BMI of 27 kg/m2 or higher living
in the greater area of Leiden (in the West of The Netherlands) were
eligible to participate in the NEO study. In addition, all inhabitants
aged between 45 and 65 years from one municipality (Leiderdorp)
were invited, irrespective of their BMI.
Prior to the NEO study visit, participants completed a ques-
tionnaire about demographic and clinical data and fasted for at
least 10 h. Participants came to the research site in the morning to
undergo several baseline measurements including anthropo-
metric measurements, blood sampling and a cIMT measurement.
For the present analysis, we excluded participants who used oral
hypoglycemic agents or insulin in the month prior to the study
visit, in addition to participants with missing data.
The study was approved by the medical ethics committee of the
Leiden University Medical Center (LUMC) and all participants gave
written informed consent.
2.2. Data collection
Participants reported ethnicity by self-identiﬁcation in eight
categories which we grouped into white (reference) and other.
Tobacco smoking was reported in the three categories current
smoker, former smoker, never smoker (reference). Highest level of
education was reported in 10 categories according to the Dutch
education system and grouped into high versus low education
(reference). Participants reported their medical history of diabetes
and cardiovascular diseases. Pre-existing cardiovascular disease
was deﬁned as myocardial infarction, angina, congestive heart
failure, stroke, or peripheral vascular disease. In addition, all use of
medication in the month preceding the study visit was recorded. At
the study site, height andweight weremeasuredwithout shoes and
with precision of 0.1 cm/kg and 1 kg was subtracted from the
weight for clothing. BMI was calculated by dividing the weight in
kilograms by the height in meters squared. Waist circumference
was measured between the border of the lower costal margin and
the iliac crest with the precision of 0.1 cm. We used BMI as a
measure of overall adiposity and waist circumference as a measure
of abdominal adiposity.
2.3. Measures of insulin resistance and glycemic control
Fasting blood samples were drawn from the antecubal vein
after 5 min rest of the participant. Fasting plasma glucose con-
centrations (FPG) were determined by enzymatic and colorimetric
methods (Roche Modular Analytics P800, Roch Diagnostics, Man-
nheim, Germany; CV < 5%) and serum insulin concentrations
were determined by an immunometric method (Siemens Immulite
2500, Siemens Healthcare Diagnostics, Breda, The Netherlands;
CV < 5%). HbA1c concentrations were measured by HPLC boronate
afﬁnity chromatography (Primus Ultra, Siemens Healthcare Di-
agnostics, Breda, The Netherlands; CV < 3%). All analyses were
performed in the central clinical chemistry laboratory of the
LUMC [13].
In our study population without glucose lowering therapy, we
identiﬁed individuals with unknown diabetes, having a FPG of
7.0 mmol/L or higher. FPG reﬂects basal gluconeogenesis and HbA1c
represents the average glucose concentration in the preceding
3months [14]. The updated Homeostasis Model Assessment Insulin
Resistance (HOMA-IR) is a measure of insulin resistance, which
corresponds well to estimates of insulin resistance derived from the
hyperinsulinemic euglycemic clamp [15], and it was calculated by
entering fasting glucose and fasting insulin in a Microsoft Excel
spreadsheet available on the internet [16].
Table 1
Baseline characteristics of the weighted NEO study population of 6065 participants
in the NEO study aged between 45 and 65 years without glucose lowering therapy.
Characteristics NEO study population
(n ¼ 6065)
Age (years) 56 (50e61)
Sex (% men) 43
Ethnicity (% whites) 95
Educational level (% low a) 19
Tobacco smoking (%)
Current 16
Former 46
Medical history of CVD b (%) 6
BMI (kg/m2) 26.2 (4.3)
Waist circumference (cm)
Men 98 (11)
Women 87 (13)
FPG (mmol/L) 5.4 (0.8)
 7.0 mmol/L (%) 2
HbA1c (% Hb) 5.3 (0.3)
HOMA-IR 0.85 (0.81)
cIMT (mm) 616 (92)
Data are shown as mean (SD), median (IQR) or number (%).
a Low education: none, primary school, lower vocational education.
b CVD: cardiovascular disease; deﬁned as myocardial infarction, angina,
congestive heart failure, stroke and peripheral vascular disease.
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The cIMT was measured in the far wall of the left and right
common carotid arteries (CCA’s), along a 15 mm long section
10 mm, proximal of the bifurcation, and in recumbent position. A
7.5e10 MHz linear-array transducer (Art.Lab version 2.1, Esaote,
Maastricht, The Netherlands) in B-mode setting was used to visu-
alize the distal CCA and an online wall track system was used to
detect the lumen-intima and media-adventitia boundaries. CIMT
was measured in three predeﬁned angles per side (180,135 and 90
for the right CCA and 180, 225 and 270 for the left CCA) during six
heartbeats. We calculated the mean cIMT for each participant
(referred to as cIMT) by averaging all 36 cIMTmeasurements within
each individual.
2.5. Statistical analyses
In the NEO study there is an oversampling of individuals with a
BMI of 27 kg/m2 or higher. To correctly represent associations in
the general population [17], adjustments for the oversampling of
individuals with a BMI  27 were made. This was done by
weighting individuals towards the BMI distribution of participants
from the Leiderdorp municipality [18], whose BMI distribution was
similar to the BMI distribution of the general Dutch population [19].
Baseline characteristics of the weighted study population were
expressed as mean (SD), median (IQR) or as percentage. We divided
the participants who were excluded from our analyses into two
groups: those who used glucose lowering therapy and those who
did not use glucose lowering therapy, but had missing data. Dif-
ferences in baseline characteristics between these groups and the
participants who were included in our analyses were tested with
Student t-test or Chi-squared test where appropriate.
Insulin concentrations below the detection limit of the assay
(2.0 mU/L) were imputed using multiple imputation methods for
left censored data [20], with 10 imputation datasets. We calculated
Pearson’s correlation coefﬁcients between FPG, HbA1c, HOMA-IR,
BMI, waist circumference, and also between the exposures and
cIMT to be able to compare these correlation coefﬁcients with
correlation coefﬁcients from previous studies. We used generalized
additive models (GAM) to examine the shape of association be-
tween FPG, HbA1c, HOMA-IR, BMI, waist circumference and cIMT
while concurrently adjusting for age, sex, ethnicity, education, and
tobacco smoking. The associations of FPG, HbA1c, and HOMA-IR
with cIMT were additionally adjusted for BMI and waist circum-
ference. The associations between FPG, HbA1c, HOMA-IR, BMI,
waist circumference and cIMT were analyzed both in weighted
tertiles of the exposures and continuously by using linear regres-
sion analyses. FPG, HbA1c, HOMA-IR, and BMI were divided into
tertiles. In addition, we standardized the values of FPG, HbA1c,
HOMA-IR, and BMI. As a result, the differences in cIMT are
expressed per standard deviation of each variable. Waist circum-
ference was standardized for men and women separately.
Regression coefﬁcients and corresponding 95% conﬁdence in-
tervals (CI) were expressed as the difference in cIMT (mm) per tertile
(lowest tertile as reference category) and per standard deviation of
FPG, HbA1c, HOMA-IR, BMI, and waist circumference. We calculated
variance inﬂation factors (VIFs) to check for multicollinearity in our
regression models and VIF values below 10 were considered
appropriate. First, we adjusted the crude associations for age, sex,
ethnicity, education, and tobacco smoking (model 1). Second, to
study to what extent associations of FPG and HbA1c with cIMT are
explained by insulin resistance, we additionally adjusted these
associations for HOMA-IR (model 2a). Third, in order to study direct
pathways, we included intermediate variables FPG and HbA1c in the
model with HOMA-IR as exposure (model 2b) and FPG, HbA1c, andHOMA-IR in the models with BMI or waist circumference as
exposure. Fourth, to study to what extent the association between
adiposity and cIMT ismediated bymechanisms of hyperglycemia or
insulin resistance, we additionally included FPG and HbA1c (model
2d) and HOMA-IR (model 2e) in the models with BMI or waist
circumference as exposure. Finally, in order to investigate the in-
ﬂuence of adiposity, we included waist circumference and BMI in
the models with FPG, HbA1c (model 3a) or HOMA-IR (model 3b) as
exposure.
We performed a sensitivity analysis excluding participants with
pre-existing cardiovascular disease at the baseline study visit. An-
alyses were performed with STATA Statistical Software (Statacorp,
College Station, Texas, USA), version 12.0. GAM curves were
constructed with R: A language and environment for statistical
computing (R Foundation for Statistical Computing, Vienna,
Austria. ISBN 3-900051-07-0, URL http://www.R-project.org),
version 2.15.0.
3. Results
6673 participants were included in the NEO study. After
consecutive exclusion of participants who used oral hypoglycaemic
agents (n¼ 267), insulin (n¼ 23) or both (n¼ 66), participants with
missing fasting blood sampling (n ¼ 117), missing cIMT data
(n ¼ 66) or missing data for ethnicity (n ¼ 9), education (n ¼ 56),
tobacco smoking (n ¼ 3) or waist circumference (n ¼ 1), 6065
participants were included in the present analysis.
Characteristics of the included participants are presented in
Table 1. When compared with the included participants, excluded
participants who used glucose lowering therapy (n ¼ 356) were
older (mean age 59 versus 56), more frequently male (55% versus
43%), had a higher mean BMI (31.0 kg/m2 versus 26.2 kg/m2), and
had a higher mean cIMT (655 mm versus 616 mm). There were no
differences in baseline characteristic between the included partic-
ipants and excluded participants who did not use glucose lowering
therapy (n ¼ 252) (data not shown).
The Pearson correlation coefﬁcients between FPG, HbA1c,
HOMA-IR, BMI, waist circumference, and cIMT are shown in
Supplemental Material Table 1. The GAM curves showed linear
associations between FPG, HbA1c, HOMA-IR, BMI, waist circumfer-
ence and cIMT after adjusting for confounding variables (Fig. 2).
5.0 5.5 6.0 6.5
63
0
65
0
67
0
FPG (mmol/L)
cI
M
T 
(µm
)
5.0 5.2 5.4 5.6 5.8 6.0
63
0
65
0
67
0
HbA1c (%Hb)
cI
M
T 
(µm
)
0.5 1.0 1.5 2.0 2.5
63
0
65
0
67
0
HOMA−IR
cI
M
T 
(µm
)
25 30 35 40
63
0
65
0
67
0
BMI (kg/m2)
cI
M
T 
(µm
)
90 100 110 120
62
0
64
0
66
0
Waist circumference (cm)
cI
M
T 
(µm
)
Fig. 2. Generalized Additive Model curves showing the associations between FPG,
HbA1c, HOMA-IR, BMI, waist circumference and cIMT in 6065 participants in the NEO
study aged between 45 and 65 years without glucose lowering therapy. Curves were
adjusted for age, sex, ethnicity, education, and tobacco smoking. The associations of
FPG, HbA1c, and HOMA-IR with cIMT were additionally adjusted for BMI and waist
circumference.
Table 2
Associations between tertiles of FPG, HbA1c, HOMA-IR, BMI, waist circumference
and cIMT (mm) in 6065 participants in the NEO study aged between 45 and 65 years
without glucose lowering therapy.
Tertiles Difference in cIMT (mm)a
Crude
(95% CI)
Model 1
(95% CI)
Model 2a/b/c
(95% CI)
Model 3a/b
(95% CI)
FPG (mmol/L) Model 2a Model 3a
<5.1 (reference) e e e e
5.1e5.5 26 (17, 35) 18 (10, 27) 17 (8, 25) 13 (4, 21)
>5.5 43 (35, 51) 24 (16, 32) 19 (11, 28) 11 (3, 19)
HbA1c (%Hb) Model 2a Model 3a
<5.2 (reference) e e e e
5.2e5.4 16 (7, 25) 8 (0, 17) 7 (1, 15) 5 (3, 13)
>5.4 31 (22, 39) 16 (8, 24) 12 (3, 20) 4 (4, 13)
HOMA-IR Model 2b Model 3b
<0.78 (reference) e e e e
0.78e1.22 12 (1, 22) 8 (2, 18) 6 (4, 16) 1 (9, 11)
>0.90 31 (23, 39) 23 (15, 31) 18 (9, 26) 0 (9, 9)
BMI (kg/m2) Model 2c
<24.0 (reference) e e e e
24.0e27.2 31 (21, 40) 25 (16, 34) 23 (14, 33) e
>27.2 48 (41, 56) 42 (35, 50) 38 (30, 46) e
Waist circumference
(cm)
Model 2c
<85 (reference) e e e e
85e97 27 (17, 36) 19 (10, 27) 16 (7, 25) e
>97 51 (43, 59) 40 (32, 48) 34 (25, 43) e
Model 1: Adjusted for age, sex, ethnicity, education, and tobacco smoking.
Model 2a: Adjusted for model 1 plus HOMA-IR.
Model 2b: Adjusted for model 1 plus HbA1c and FPG.
Model 2c: Adjusted for model 1 plus HOMA-IR, HbA1c, and FPG.
Model 3a: Adjusted for model 2a plus waist circumference and BMI.
Model 3b: Adjusted for model 2b plus waist circumference and BMI.
a Beta coefﬁcients (95% CI) from linear regression.
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tiles in Table 2 and per standard deviation of FPG, HbA1c, HOMA-IR,
BMI, and waist circumference in Fig. 3. One standard deviation of
FPG (0.8 mmol/L) was associated with 16 (95% CI: 10, 21) mm cIMT.
One standard deviation of HbA1c (0.3%) was associated with 12 mm
cIMT (95% CI: 7, 16). These associations attenuated after adjustment
for age, sex, ethnicity, education, and tobacco smoking (FPG: 9 mm,
95% CI: 5, 13; HbA1c: 6 mm, 95% CI: 3, 10) and attenuated further
after adjustment for HOMA-IR (FPG: 6 mm, 95% CI: 3, 10; HbA1c:
4 mm, 95% CI: 1, 8). After additional adjustment for BMI and waistcircumference, the cIMT difference was 4 mm (95% CI: 0, 7) per
standard deviation of FPG and 2 mm (95% CI:1, 5) per one standard
deviation of HbA1c (Fig. 3a and b). Of all confounding variables,
association between FPG, HbA1c, and cIMT attenuated most
strongly after adjustment for waist circumference.
The crude association of one standard deviation of HOMA-IR
(0.81 units) of 11 mm cIMT (95% CI: 6, 16) attenuated to 9 mm
(95% CI: 5, 12) after adjustment for age, sex, ethnicity, education,
and tobacco smoking and to 6 mm (95% CI: 3, 10) after adjustment
for HbA1c and FPG. After additional adjustment for both BMI and
waist circumference the cIMT difference was 0 mm (95% CI: 3, 3)
(Fig. 3c). Of all confounding variables, the association between
HOMA-IR and cIMT attenuated most strongly after adjustment for
waist circumference.
One standard deviation of BMI (4.3 kg/m2) was associated with
19 mm cIMT (95% CI: 16, 21). One standard deviation of waist
circumference (men: 11 cm;women: 13 cm)was associatedwith 19
(95% CI: 17, 21) mm cIMT. These associations attenuated after
adjustment for age, sex, ethnicity, education, and tobacco smoking
(BMI: 17 mm, 95% CI: 14, 20; waist circumference: 19 mm, 95% CI: 16,
22) (Fig. 3). After additional adjustment for FPG, HbA1c, and HOMA-
IR, the cIMT differences was 16 mm cIMT (95% CI: 13,19) for BMI and
18 mmcIMT (95% CI: 14, 21) for waist circumference. The differences
in cIMT were similar when we adjusted separately for FPG and
HbA1c and HOMA-IR (Fig. 3d and e).
After exclusion of participants with pre-existing cardiovascular
disease results were similar (data not shown).4. Discussion
In this population-based study of men and women without
glucose lowering medication, we observed that both insulin
BMI (SD: 4.3 kg/m
2
)
0 10 20
Model 2e        
Model 2d        
Model 2c        
Model 1        
Crude        
Difference in cIMT (µ  m)
FPG (SD: 0.8 mmol/L)
0 10 20
Model 3a        
Model 2a        
Model 1        
Crude        
Difference in cIMT (µ  m)
HbA1
c
(SD: 0.3%)
0 10 20
Model 3a        
Model 2a        
Model 1        
Crude        
Difference in cIMT (µ  m)
HOMA-IR (SD: 0.81)
0 10 20
Model 3b        
Model 2b        
Model 1        
Crude        
Difference in cIMT (µ  m)
Waist circumference (SD: 11/13 cm (m/w))
0 10 20
Model 2e        
Model 2d        
Model 2c        
Model 1        
Crude        
Difference in cIMT (   m)µ  
a
b
c
d
e
K.B. Gast et al. / Atherosclerosis 229 (2013) 423e429 427resistance and hyperglycemia remained associated with cIMT after
mutual adjustment. Importantly, abdominal adiposity largely
explained these associations.
Several studies have investigated associations between insulin
resistance, hyperglycemia and cIMT, a marker of subclinical
atherosclerosis. The correlation coefﬁcients between HbA1c, FPG,
HOMA-IR, BMI, waist circumference and cIMT from our study were
within the range of correlation coefﬁcients observed in previous
studies [8e10,21e24]. However, relative contributions of hyper-
glycemia, insulin resistance and adiposity to the development of
atherosclerosis were not identiﬁed in these studies. A recent study
in 60 middle-aged individuals without diabetes concluded that the
association between plasma glucose concentrations and cardio-
vascular risk was mainly explained by insulin resistance [25].
However, after adjustment for insulin sensitivity FPG remained
associated with the cardiovascular risk score. In our study of 6065
participants, in which we assessed a clinical parameter of subclin-
ical atherosclerosis instead of a risk calculator, both insulin resis-
tance and glucose concentrations remained associated with the
cIMT after mutual adjustment. These associations were of similar
strength, suggesting that both play a role in the development of
atherosclerosis. However, in our study, waist circumference was
most strongly associated with the cIMT, and largely explained the
association of hyperglycemia with cIMT and completely explained
the association of insulin resistance with cIMT. This implies that
abdominal adiposity is for a large part responsible for the devel-
opment of insulin resistance, hyperglycemia and subclinical
atherosclerosis.
Strengths of this study are the large study population and the
availability of a clinical parameter of atherosclerosis, information
on measures of glycemic control, potential confounding variables,
and of waist circumference as a measure of abdominal adiposity
besides BMI.
This study also has some limitations that need to be considered.
We assessed insulin resistance using the HOMA-IR instead of using
a gold standard measurement, the hyperinsulinemic euglycemic
clamp. However, the application of hyperinsulinemic euglycemic
clamps in large epidemiologic studies is often not feasible. HOMA-
IR is a surrogate measure of insulin resistance and may therefore
not account for the total effect of insulin resistance [15]. Since waist
circumference is strongly associated with insulin resistance [26],
adjustment for waist circumference in addition to HOMA-IR may
have resulted in a more complete adjustment for insulin resistance.
However, due to the observational cross-sectional nature of our
analyses, residual confounding may remain.
Data from experimental studies have shown that both insulin
resistance and hyperglycemia can promote the development of
atherosclerosis [3,4]. Whereas insulin resistance seems to be
involved in both early atherosclerosis and advanced plaque pro-
gression (Fig. 1, path B), the effects of hyperglycemia seem to be
limited to the development of early atherosclerosis (Fig. 1, path E)
[4]. This might explain why interventions that improve glycemic
control have not resulted in a reduction of cardiovascular events in
patients with type 2 diabetes [6] and in persons with pre-diabetes
and a prior cardiovascular event [7], who are likely to haveFig. 3. Associations between standardized FPG (3a), HbA1C (3b), HOMA-IR (3c), BMI
(3d), waist circumference (3e) and cIMT (mm) in 6065 participants in the NEO study
aged between 45 and 65 years without glucose lowering therapy. Model 1: Adjusted
for age, sex, ethnicity, education, and tobacco smoking. Model 2a: Adjusted for model 1
plus HOMA-IR. Model 2b: Adjusted for model 1 plus HbA1c and FPG. Model 2c:
Adjusted for model 1 plus HOMA-IR, HbA1c, and FPG. Model 2d: Adjusted for model 1
plus HbA1c and FPG. Model 2e: Adjusted for model 1 plus HOMA-IR. Model 3a:
Adjusted for model 2a plus waist circumference and BMI. Model 3b: Adjusted for
model 2b plus waist circumference and BMI.
K.B. Gast et al. / Atherosclerosis 229 (2013) 423e429428underlying intermediate or advanced atherosclerosis. In addition,
the cardiovascular risk reduction of 42% by intensive glycemic
control in a trial in patients with type 1 diabetes may support the
hypothesis that glucose lowering therapy early in the course of
atherosclerosis is beneﬁcial [27]. The results of our study suggest
that hyperglycemia may and insulin resistance may not contribute
to the development of atherosclerosis in a population of individuals
with low cIMT, possibly reﬂecting an early stage of atherosclerosis.
Even though associations between hyperglycemia and subclinical
atherosclerosis were weak, one cannot rule out the possibility that
small effects can accumulate over time.
In our study, waist circumference most strongly explained the
association between insulin resistance, hyperglycemia and sub-
clinical atherosclerosis, implying underlying pathways between
abdominal adiposity and atherosclerosis beyond pathways via in-
sulin resistance and glucose. We furthermore observed that the
association between waist circumference and subclinical athero-
sclerosis attenuated slightly after adjustment for hyperglycemia
and insulin resistance, suggesting that it is partly mediated through
insulin resistance and hyperglycemia, but largely through other
mechanisms. Associations attenuated to the same extent when
adjusting for insulin resistance and hyperglycemia together and
separately, suggesting that both reﬂect the same mechanism.
Observational studies support that abdominal adiposity is a
better marker of cardiometabolic risk and mortality than overall
adiposity [28]. Adipose tissue is an endocrine organ secreting pro-
inﬂammatory cytokines and non-esteriﬁed fatty acids (NEFA’s)
[29], that may promote the development of insulin resistance
(Fig. 1, path C) and atherosclerosis (Fig. 1, path A) via mechanisms of
inﬂammation and oxidative stress [3,30]. Adipose tissue may
therefore promote the development of atherosclerosis through
insulin resistance (Fig. 1, path CB) and hyperglycemia (Fig. 1, path
CDE), but also directly by mechanism such as inﬂammation, dys-
lipidemia and hypertension (Fig. 1, path A) [30]. Especially intra-
abdominal adipose tissue is a major source of adipokines and
NEFA’s [31], and waist circumference has been shown to be an
adequate marker of abdominal adiposity [32]. Several weight loss
studies have shown that cardiometabolic improvements were
related to the extent of intra-abdominal adipose tissue loss [33,34].
Therefore, health beneﬁts can be gained from weight loss in-
terventions in individuals with abdominal adiposity.
In conclusion, in middle-aged individuals without glucose
lowering medication we observed similar contributions of insulin
resistance and hyperglycemia to the development of subclinical
atherosclerosis. These contributions were to a large extent
explained by abdominal adiposity, emphasizing the importance
of weight management and prevention of weight gain in
adulthood.
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